Treatment of Radiation Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)
Phase 2
Terminated
- Conditions
- Eye Injuries
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-06-21
- Lead Sponsor
- Manhattan Eye, Ear & Throat Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT00211367
- Locations
- ๐บ๐ธ
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States
Treatment of Diabetic Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)
Phase 1
Terminated
- Conditions
- Diabetic Retinopathy
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-05-08
- Lead Sponsor
- Manhattan Eye, Ear & Throat Hospital
- Registration Number
- NCT00211406
- Locations
- ๐บ๐ธ
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States
Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.
Phase 2
Completed
- Conditions
- Age-Related Macular Degenerations.Subfoveal Neovascularization.
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-05-07
- Lead Sponsor
- Manhattan Eye, Ear & Throat Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT00211484
- Locations
- ๐บ๐ธ
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States
Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).
Phase 2
Terminated
- Conditions
- Severe Diabetic RetinopathyCentral Retinal Vein OcclusionChronic InflammationInfectious Diseases
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-05-07
- Lead Sponsor
- Manhattan Eye, Ear & Throat Hospital
- Registration Number
- NCT00211471
- Locations
- ๐บ๐ธ
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States
Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.)
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2009-02-04
- Lead Sponsor
- Manhattan Eye, Ear & Throat Hospital
- Registration Number
- NCT00211354
- Locations
- ๐บ๐ธ
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States
Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)
Phase 2
Completed
- Conditions
- Chronic Central Serous Chorioretinopathy
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-09-28
- Lead Sponsor
- Manhattan Eye, Ear & Throat Hospital
- Target Recruit Count
- 11
- Registration Number
- NCT00211445
- Locations
- ๐บ๐ธ
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States
Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration
Phase 2
Completed
- Conditions
- Age-Related Macular Degeneration
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2007-07-12
- Lead Sponsor
- Manhattan Eye, Ear & Throat Hospital
- Target Recruit Count
- 106
- Registration Number
- NCT00140803
- Locations
- ๐จ๐ฆ
Vh/UBC Eye Care Centre, Vancouver, British Columbia, Canada
๐บ๐ธManhattan Eye, Ear & Throat Hospital, New York, New York, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath